Biomarkers for Muscle Function and Aging in Chronic HIV Infection



Status:Active, not recruiting
Conditions:HIV / AIDS, HIV / AIDS
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:50 - 65
Updated:1/20/2018
Start Date:February 2015
End Date:February 2020

Use our guide to learn which trials are right for you!

MATCH is an observation study of HIV-infected adults on effective antiretroviral therapy
(ART) and demographically matched uninfected adults to evaluate muscle and aging.

MATCH is a non-randomized observational longitudinal study. We will recruit HIV infected
adults (50 to 65 years old) and demographically matched uninfected control subjects to be
followed for 4 years over the course of a 5 year study. The targeted age range of 50-65 is
chosen to evaluate aging HIV infected individuals at risk for early frailty in the United
States. All subjects will undergo blood draws and physical function assessment, and a subset
will undergo a CT scan of muscle and will have a muscle biopsy taken.

A substudy will be performed on a subgroup of HIV-infected and HIV-uninfected men from the
main cohort to measure daily physical activity by using an activity tracker.

Inclusion Criteria:

Group 1: HIV positive subjects

- HIV positive

- English speaking

- 50-65 years old

- On Antiretroviral therapy and an HIV viral load below 200 copies/ml

- CD4 equal to or greater than 350 cells/mm3

- Postmenopausal (women)

- Lower extremity mobility sufficient to participate in functional assessment.

Group 2: HIV negative subjects Inclusion Criteria for Group 2 subjects

- English speaking

- 50-65 years old

- Negative for HIV (based on an HIV antibody test at Study Visit 1)

- Matched to Group 1 for sex (50% W, 50% M) and age (50 - 65yo)

- Postmenopausal (women)

- Lower extremity mobility sufficient to participate in functional assessment.

Exclusion Criteria:

Exclusion Criteria for Group 1 Subjects

- Acute or serious illness within 60 days prior to entry

- Use of pharmacologic doses of corticosteroids in the past 6 months.

- Use of anabolic therapy in the past 6 months.

- Lower extremity mobility insufficient to participate in functional assessment.

- Current use (last 30 days) of anticoagulants or known bleeding disorder.

Exclusion Criteria for Group 2 subjects

- Acute or serious illness within 60 days prior to entry

- Use of pharmacologic doses of corticosteroids in the past 6 months

- Use of anabolic therapy in the past 6 months

- Lower extremity mobility insufficient to participate in functional assessment

- Current use (last 30 days) of anticoagulants or known bleeding disorder.
We found this trial at
1
site
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials